These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16362634)

  • 1. Neuropathological changes in ten cases of neuronal intermediate filament inclusion disease (NIFID): a study using alpha-internexin immunohistochemistry and principal components analysis (PCA).
    Armstrong RA; Kerty E; Skullerud K; Cairns NJ
    J Neural Transm (Vienna); 2006 Sep; 113(9):1207-15. PubMed ID: 16362634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laminar degeneration of the frontal and temporal cortex in neuronal intermediate filament inclusion disease (NIFID): a study original using alpha-internexin immunohistochemistry.
    Armstrong RA; Cairns NJ
    Clin Neuropathol; 2006; 25(5):209-15. PubMed ID: 17007442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial correlations between the neuronal inclusions, swollen achromatic neurons, and glial cells in neuronal intermediate filament inclusion disease (NIFID).
    Cairns NJ; Armstrong RA
    J Neural Transm (Vienna); 2005 Apr; 112(4):473-80. PubMed ID: 15375676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial patterns of the pathological changes in neuronal intermediate filament inclusion disease (NIFID): an alpha-internexin immunohistochemical study.
    Armstrong RA; Cairns NJ
    J Neural Transm (Vienna); 2007; 114(4):451-6. PubMed ID: 17109074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial patterns of the pathological changes in the temporal lobe of patients with neuronal intermediate filament inclusion disease.
    Cairns NJ; Armstrong RA
    Neuropathology; 2005 Dec; 25(4):298-303. PubMed ID: 16382778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease.
    Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
    Acta Neuropathol; 2011 Feb; 121(2):219-28. PubMed ID: 20886222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topography of alpha-internexin-positive neuronal aggregates in 10 patients with neuronal intermediate filament inclusion disease.
    Armstrong RA; Cairns NJ
    Eur J Neurol; 2006 May; 13(5):528-32. PubMed ID: 16722980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.
    Cairns NJ; Uryu K; Bigio EH; Mackenzie IR; Gearing M; Duyckaerts C; Yokoo H; Nakazato Y; Jaros E; Perry RH; Arnold SE; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2004 Sep; 108(3):213-23. PubMed ID: 15170578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basophilic inclusion body disease and neuronal intermediate filament inclusion disease: a comparative clinicopathological study.
    Yokota O; Tsuchiya K; Terada S; Ishizu H; Uchikado H; Ikeda M; Oyanagi K; Nakano I; Murayama S; Kuroda S; Akiyama H
    Acta Neuropathol; 2008 May; 115(5):561-75. PubMed ID: 18080129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the pathological changes in the temporal lobe of patients with a novel neurofilamentopathy: neurofilament inclusion disease (NID).
    Cairns NJ; Armstrong RA
    Clin Neuropathol; 2004; 23(3):107-12. PubMed ID: 15200288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID).
    Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
    J Neural Transm (Vienna); 2011 Nov; 118(11):1651-7. PubMed ID: 21792670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease.
    Cairns NJ; Grossman M; Arnold SE; Burn DJ; Jaros E; Perry RH; Duyckaerts C; Stankoff B; Pillon B; Skullerud K; Cruz-Sanchez FF; Bigio EH; Mackenzie IR; Gearing M; Juncos JL; Glass JD; Yokoo H; Nakazato Y; Mosaheb S; Thorpe JR; Uryu K; Lee VM; Trojanowski JQ
    Neurology; 2004 Oct; 63(8):1376-84. PubMed ID: 15505152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease.
    Cairns NJ; Zhukareva V; Uryu K; Zhang B; Bigio E; Mackenzie IR; Gearing M; Duyckaerts C; Yokoo H; Nakazato Y; Jaros E; Perry RH; Lee VM; Trojanowski JQ
    Am J Pathol; 2004 Jun; 164(6):2153-61. PubMed ID: 15161649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topography of hemispheric white matter pathology in ten cases of neuronal intermediate filament inclusion disease.
    Armstrong RA
    Clin Neuropathol; 2018; 37(5):239-244. PubMed ID: 29956645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal intranuclear inclusions are ultrastructurally and immunologically distinct from cytoplasmic inclusions of neuronal intermediate filament inclusion disease.
    Mosaheb S; Thorpe JR; Hashemzadeh-Bonehi L; Bigio EH; Gearing M; Cairns NJ
    Acta Neuropathol; 2005 Oct; 110(4):360-8. PubMed ID: 16025283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
    Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
    J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.
    Gelpi E; Lladó A; Clarimón J; Rey MJ; Rivera RM; Ezquerra M; Antonell A; Navarro-Otano J; Ribalta T; Piñol-Ripoll G; Pérez A; Valldeoriola F; Ferrer I
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):795-805. PubMed ID: 22892522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending the clinicopathological spectrum of neurofilament inclusion disease.
    Josephs KA; Uchikado H; McComb RD; Bashir R; Wszolek Z; Swanson J; Matsumoto J; Shaw G; Dickson DW
    Acta Neuropathol; 2005 Apr; 109(4):427-32. PubMed ID: 15754170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal lobe pathology of human patients with neurofilament inclusion disease.
    Cairns NJ; Jaros E; Perry RH; Armstrong RA
    Neurosci Lett; 2004 Jan; 354(3):245-7. PubMed ID: 14700742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An autopsy case of neuronal intermediate filament inclusion disease with regard to immunophenotypic and topographical analysis of the neuronal inclusions.
    Inoue K; Fujimura H; Ueda K; Matsumura T; Itoh K; Sakoda S
    Neuropathology; 2015 Dec; 35(6):545-52. PubMed ID: 26096780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.